Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – November 8, 2023 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Adams

DUR Board Members:

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Vineetha Thomas –	participating in person
Dr. Beth Walton –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://oklahoma.zoom.us/webinar/register/WN_R_AmCBepQpGQggKXT40uxg
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 919 6475 4191
Passcode: 95646190

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. October 11, 2023 DUR Board Meeting Minutes
   B. October 11, 2023 DUR Board Recommendations Memorandum

Items to be presented by Dr. Morgan, Dr. O'Halloran Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/ Use of Statins in Members with Diabetes Mellitus (DM) – See Appendix B**
   A. Pharmacy Help Desk Activity for October 2023
   B. Medication Coverage Activity for October 2023
   C. Use of Statins in Members with DM

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

5. **Action Item – Approval of 2024 DUR Board Meeting Dates – See Appendix C**

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Elevidys (Delandistrogene Moxeparvovec-rokl) and Update the Approval Criteria for the Muscular Dystrophy Medications – See Appendix D**
   A. Market News and Updates
   B. Elevidys (Delandistrogene Moxeparvovec-rokl) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Jesduvroq™ (Daprodustat) and Update the Approval Criteria for the Anemia Medications – See Appendix E**
   A. Market News and Updates
   B. Jesduvroq™ (Daprodustat) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Idacio® (Adalimumab-aacf), Litfulo™ (Ritlecitinib), Tofidence™ (Tocilizumab-bavi), Yuflyma® (Adalimumab-aaty), and Yusimry™ (Adalimumab-aqvh) and Update the Approval Criteria for the Targeted Immunomodulator Agents – See Appendix F**
   A. Market News and Updates
   B. Product Summaries
   C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

9. **Action Item – Vote to Prior Authorize Veopoz™ (Pozelimab-bbfg) – See Appendix G**
   A. Market News and Updates
   B. Veopoz™ (Pozelimab-bbfg) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

10. **Action Item – Vote to Prior Authorize Ojjaara (Momelotinib) – See Appendix H**
    A. Market News and Updates
    B. Ojjaara (Momelotinib) Product Summary
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

11. **Action Item – Annual Review of Atopic Dermatitis (AD) Medications – See Appendix I**
    A. Current Prior Authorization Criteria
    B. Utilization of AD Medications
    C. Prior Authorization of AD Medications
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of AD Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

12. **Action Item – Annual Review of Injectable and Vaginal Progesterone Products – See Appendix J**
    A. Current Prior Authorization Criteria

B. Utilization of Injectable and Vaginal Progesterone Products
C. Prior Authorization of Injectable and Vaginal Progesterone Products
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Injectable and Vaginal Progesterone Products

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

13. **Annual Review of Multiple Myeloma Medications and 30-Day Notice to Prior Authorize Elrexfio™ (Elranatamab-bcmm) and Talvey™ (Talquetamab-tgvs) – See Appendix K**

A. Current Prior Authorization Criteria
B. Utilization of Multiple Myeloma Medications
C. Prior Authorization of Multiple Myeloma Medications
D. Market News and Updates
E. Product Summaries
F. College of Pharmacy Recommendations
G. Utilization Details of Multiple Myeloma Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

14. **Annual Review of Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications and 30-Day Notice to Prior Authorize Symbicort Aerosphere® (Budesonide/Formoterol Fumarate) – See Appendix L**

A. Current Prior Authorization Criteria
B. Utilization of Asthma and COPD Maintenance Medications
C. Prior Authorization of Asthma and COPD Maintenance Medications
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Asthma and COPD Maintenance Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

15. **30-Day Notice to Prior Authorize Sohonos™ (Palovarotene) – See Appendix M**

A. Introduction
B. Sohonos™ (Palovarotene) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

16. **Annual Review of Vasomotor Symptom (VMS) Medications and 30-Day Notice to Prior Authorize Veozah™ (Fezolinetant) – See Appendix N**

A. Current Prior Authorization Criteria
B. Utilization of VMS Medications
C. Prior Authorization of VMS Medications
D. Market News and Updates
E. Veozah™ (Fezolinetant) Product Summary

F. College of Pharmacy Recommendations
G. Utilization Details of VMS Medications

Items to be presented Dr. Morgan, Dr. Muchmore, Chairman:

17. Annual Review of Dry Eye Disease (DED) Medications and 30-Day Notice to Prior Authorize Miebo™ (Perfluorohexyloctane Ophthalmic Solution) and Vevye® (Cyclosporine Ophthalmic Solution) – See Appendix O

A. Current Prior Authorization Criteria
B. Utilization of DED Medications
C. Prior Authorization of DED Medications
D. Market News and Updates
E. Product Summaries
F. College of Pharmacy Recommendations
G. Utilization Details of DED Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

18. Annual Review of Skysona® (Elivaldogene Autotemcel) – See Appendix P

A. Current Prior Authorization Criteria
B. Utilization of Skysona® (Elivaldogene Autotemcel)
C. Prior Authorization of Skysona® (Elivaldogene Autotemcel)
D. College of Pharmacy Recommendations

Items to be presented by Dr. Morgan, Dr. Muchmore, Chairman:

19. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix Q

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

20. Future Business* (Upcoming Product and Class Reviews)

A. Anticoagulants and Platelet Aggregation Inhibitors
B. Antidepressants
C. Lysosomal Storage Disease Medications
D. Skin Cancer Medications

*Future product and class reviews subject to change.

21. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.